Xeris Biopharma Holdings, Inc. — Form 8-K Summary
Reporting date: September 29, 2023. The filing reports the closing of an exchange transaction involving Xeris Biopharma Holdings, Inc. and its wholly owned subsidiary, Xeris Pharmaceuticals, Inc. It does not provide operating results for revenue, profitability, cash flow, margins, or liquidity.
Material Financing Transaction
- The company exchanged $31.975 million aggregate principal amount of Xeris Pharmaceuticals’ 5.00% Convertible Senior Notes due 2025 for $33.574 million aggregate principal amount of the company’s new 8.00% Convertible Senior Notes due 2028.
- The transaction extended the stated maturity from 2025 to July 15, 2028 and increased the coupon from 5.00% to 8.00%.
- The New Notes are senior, unsecured obligations of the company and are guaranteed by Xeris Pharmaceuticals.
- Interest is payable semi-annually in arrears on January 15 and July 15, beginning January 15, 2024. The company also agreed to pay accrued interest on the Existing Notes from July 15, 2023 through the exchange date to New Note holders on January 15, 2024.
- The New Notes were issued in a private transaction under the Securities Act Section 4(a)(2) exemption and were not registered under the Securities Act.
Conversion, Redemption, and Repurchase Terms
- The initial conversion rate is 326.7974 shares per $1,000 principal amount, equivalent to an initial conversion price of approximately $3.06 per share.
- Holders may generally convert the New Notes at any time through the second scheduled trading day before maturity, subject to the indenture’s terms.
- Upon certain Fundamental Changes, holders may require repurchase at 100% of principal plus accrued and unpaid interest.
- Beginning July 20, 2026, the company may redeem the notes in whole, but not in part, if specified stock-price conditions are satisfied. The redemption price is principal plus accrued and unpaid interest.
- In certain Make-Whole Fundamental Change scenarios, the conversion rate may increase, subject to a maximum of 549.4505 shares per $1,000 principal amount. The filing states that up to 18,447,251 common shares, subject to adjustment, could be issued upon conversion in such circumstances.
Financial and Legal Implications
- The exchange increased the principal amount of the obligations by $1.599 million, from $31.975 million to $33.574 million.
- At the 8.00% coupon, annual cash interest on the full New Notes principal would be approximately $2.686 million, before considering conversions, redemptions, repurchases, or other adjustments.
- The higher interest rate increases the company’s ongoing cash interest burden relative to the Existing Notes; the filing does not provide a broader liquidity forecast or debt-service analysis.
- The notes include customary covenants and events of default. Certain reporting-covenant failures may be subject to a special-interest remedy for up to 360 days if the company makes the applicable election.
- Unregistered shares issued upon conversion may not be offered or sold in the United States absent registration or an applicable exemption.
Outlook, Risks, and Unusual Items
The filing provides no operating guidance or management outlook. Key risks include the higher coupon, future cash requirements for interest and potential repurchases, dilution from conversion, and potential acceleration of the debt following specified events of default. The filing does not state whether any notes were converted at closing or provide the post-transaction ownership impact.
Key Facts for Investors to Verify
- Final outstanding principal balance and ownership of the New Notes following the exchange.
- Actual cash interest payments and their effect on liquidity.
- Potential common-share dilution using the initial conversion price and the maximum make-whole conversion rate.
- Details of the indenture’s covenants, events of default, and Fundamental Change provisions.
- Whether the company subsequently registers the notes or underlying shares, or whether additional exchanges, conversions, repurchases, or refinancing occur.